| |
Stemina Biomarker Discovery is a metabolomics company focused on the discovery, development and commercialization of molecular biomarkers to improve drug safety and human health. Stemina’s cell based assays arise from the strategic convergence of two cutting edge technologies: human embryonic stem (hES) cells and metabolomics. Stemina uses mass spectrometry to analyze the small molecules secreted by hES cells, and differentiated cells such as heart and neural cells made from hES cells, in response to drugs, injury or disease. Stemina opened its state-of-the-art facilities for hES cell culture and mass spectrometry in the UW Research Park in Madison Wisconsin on November 1, 2007.
Stemina News
-
CIT and Stemina Ink Deal in Europe | 2011-02-17
Stemina announces the recent strategic partnership between Stemina and CIT in Evreux, France. Under this partnership, CIT will distribute Stemina’s assays in Europe leveraging CIT’s considerable reputation and expertise to bring Stemina’s cutting edge technology for predictive toxicology to the market.
-
Stem cell scientists stress need for continued support of human embryonic stem cell research | 2010-10-26
Concerned by election rhetoric that portrays adult stem cells as adequate substitutes for human embryonic stem cells, several leading scientists joined with a patient advocate and the
founders of a growing biotechnology company Tuesday to set the record straight before voters head to the polls next week.
-
Stemina CEO Responds to Stem Cell Ruling and Wisconsin State Joural Article | 2010-08-25
I wanted to take a minute to send you some accurate information about the facts as they relate to Stemina. Having worked on the legal and political aspects of this important technology since Dr. Thomson was the first to isolate hESC in 1998 at the University of Wisconsin while I served as General Counsel for the Wisconsin Alumni Research Foundation (WARF), my experience tells me that the ruling will be overturned. Already, appeals are being filed and I am confident that very quickly the preliminary injunction will be lifted so that federal funding can still be used on the approved lines - which Stemina uses exclusively - while things get sorted out in the courts and legislature.
-
Stemina Featured in GenomeWeb's Startup Focus | 2010-05-27
Leveraging one of the newer 'omics fields along with stem cell technology, start-up firm Stemina Biomarker Discovery is looking to accelerate its work at developing metabolomic biomarkers for drug screening and efficacy and the detection of diseases.
-
Agilent Technologies Announces Collaboration with Stemina | 2010-05-24
Agilent Technologies Inc. and Stemina Biomarker Discovery, Inc. today announced efforts to accelerate Stemina's metobolomic research. Agilent is providing a 1290 Infinity UHPLC system to separate stem cellular metabolites, coupled to a 6530 Accurate Mass quadrupole time-of-flight mass spectrometer (Q-TOF MS) to identify those metabolites. Agilent also is providing Mass Profiler Professional software to help Stemina researchers interpret the complex data generated by metabolomics experiments.
|